Innovation
2 patent families (1 granted) — focus: Human necessities; filing pace steady. Cited 27 times.
| Year | Filings |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Investor mix
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |
Translational drug development company specializing in late-stage therapeutics
2 patent families (1 granted) — focus: Human necessities; filing pace steady. Cited 27 times.
| Year | Filings |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
1 investor on record.
| Investor type | Count | Share |
|---|---|---|
| Other / undisclosed | 1 | 100% |